미국 · 보도자료 · Spyre Therapeutics, Inc. · 2026-10-06 00:13
스파이어 테라퓨틱스, 3억 5,000만 달러 규모 보통주 공모 발행가 확정
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its prev
Spyre Therapeutics, Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
